Mendel I, Kerlero de Rosbo N, Ben-Nun A
Department of Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
Eur J Immunol. 1995 Jul;25(7):1951-9. doi: 10.1002/eji.1830250723.
A predominant response to myelin oligodendrocyte glycoprotein (MOG) was recently observed in patients with multiple sclerosis (MS). To study the possible pathogenic role of T cell response to MOG in MS, we have investigated the encephalitogenic potential of MOG. Synthetic MOG peptides, pMOG 1-21, 35-55, 67-87, 104-117 and 202-218, representing predicted T cell epitopes, were injected into C57BL/6J and C3H.SW (H-2b) mice. The mice developed significant specific T cell responses to pMOG 1-21, pMOG 35-55 and pMOG 104-117. However, pMOG 35-55 was the only MOG peptide which could induce neurological impairment. The highly reproducible disease was chronic, with ascending paralysis and neuropathology comparable with those observed in experimental autoimmune encephalomyelitis (EAE) induced by myelin basic protein or proteolipid protein, except that in H-2b mice the disease was consistently non-remitting. These features differ markedly from those which we recently observed in PL (H-2u) mice with pMOG 35-55-induced disease. In PL mice, pMOG 35-55-induces atypical chronic relapsing EAE, the expression and progression of which are unpredictable. Hence, in different mouse strains, the same MOG peptide can induce typical EAE characterized by ascending paralysis, or atypical EAE with unpredictable clinical signs. pMOG 35-55-specific T cells from H-2b mice recognized an epitope within amino acids 40-55 of the MOG molecule, and pMOG 40-55-reactive T cell lines were encephalitogenic upon transfer into syngeneic recipients. The encephalitogenic pMOG 35-55-reactive C57BL/6J T cell lines expressed V beta 1, V beta 6, V beta 8, V beta 14 and V beta 15 gene segments, and the pMOG 35-55-reactive C3H.SW T cell lines expressed V beta 1, V beta 2, V beta 6, V beta 8, V beta 10, V beta 14, and V beta 15 gene segments. However, in both mouse strains, the utilization of the V beta 8 gene product was predominant (40-43%). The highly reproducible encephalitogenic activity of pMOG 35-55 strongly suggests a pathogenic role for T cell reactivity to MOG in MS and supports the possibility that MOG may also be a primary target antigen in the disease.
最近在多发性硬化症(MS)患者中观察到对髓鞘少突胶质细胞糖蛋白(MOG)的主要反应。为了研究T细胞对MOG的反应在MS中可能的致病作用,我们研究了MOG的致脑炎性潜力。将代表预测T细胞表位的合成MOG肽pMOG 1-21、35-55、67-87、104-117和202-218注射到C57BL/6J和C3H.SW(H-2b)小鼠体内。这些小鼠对pMOG 1-21、pMOG 35-55和pMOG 104-117产生了显著的特异性T细胞反应。然而,pMOG 35-55是唯一能诱导神经功能障碍的MOG肽。这种高度可重复的疾病是慢性的,具有上行性麻痹和神经病理学表现,与髓鞘碱性蛋白或蛋白脂蛋白诱导的实验性自身免疫性脑脊髓炎(EAE)中观察到的情况相当,只是在H-2b小鼠中,疾病始终不缓解。这些特征与我们最近在pMOG 35-55诱导疾病的PL(H-2u)小鼠中观察到的情况明显不同。在PL小鼠中,pMOG 35-55诱导非典型慢性复发性EAE,其表达和进展不可预测。因此,在不同的小鼠品系中,相同的MOG肽可以诱导以上行性麻痹为特征的典型EAE,或具有不可预测临床症状的非典型EAE。来自H-2b小鼠的pMOG 35-55特异性T细胞识别MOG分子氨基酸40-55内的一个表位,并且pMOG 40-55反应性T细胞系在转移到同基因受体后具有致脑炎性。致脑炎性的pMOG 35-55反应性C57BL/6J T细胞系表达Vβ1、Vβ6、Vβ8、Vβ14和Vβ15基因片段,pMOG 35-55反应性C3H.SW T细胞系表达Vβ1、Vβ2、Vβ6、Vβ8、Vβ10、Vβ14和Vβ15基因片段。然而,在这两种小鼠品系中,Vβ8基因产物的利用占主导(40-43%)。pMOG 35-55的高度可重复的致脑炎性活性强烈提示T细胞对MOG的反应性在MS中具有致病作用,并支持MOG也可能是该疾病主要靶抗原的可能性。